349 related articles for article (PubMed ID: 25972865)
1. Pseudotype-based neutralization assays for influenza: a systematic analysis.
Carnell GW; Ferrara F; Grehan K; Thompson CP; Temperton NJ
Front Immunol; 2015; 6():161. PubMed ID: 25972865
[TBL] [Abstract][Full Text] [Related]
2. Development of Lentiviral Vectors Pseudotyped With Influenza B Hemagglutinins: Application in Vaccine Immunogenicity, mAb Potency, and Sero-Surveillance Studies.
Ferrara F; Del Rosario JMM; da Costa KAS; Kinsley R; Scott S; Fereidouni S; Thompson C; Kellam P; Gilbert S; Carnell G; Temperton N
Front Immunol; 2021; 12():661379. PubMed ID: 34108964
[TBL] [Abstract][Full Text] [Related]
3. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for
Jacobsen H; Rajendran M; Choi A; Sjursen H; Brokstad KA; Cox RJ; Palese P; Krammer F; Nachbagauer R
mBio; 2017 Sep; 8(5):. PubMed ID: 28928215
[TBL] [Abstract][Full Text] [Related]
4. Vaccine Efficacy of Inactivated, Chimeric Hemagglutinin H9/H5N2 Avian Influenza Virus and Its Suitability for the Marker Vaccine Strategy.
Kim SM; Kim YI; Park SJ; Kim EH; Kwon HI; Si YJ; Lee IW; Song MS; Choi YK
J Virol; 2017 Mar; 91(6):. PubMed ID: 28077631
[TBL] [Abstract][Full Text] [Related]
5. Characterization of lentiviral pseudotypes with influenza H5N1 hemagglutinin and their performance in neutralization assays.
Wang W; Xie H; Ye Z; Vassell R; Weiss CD
J Virol Methods; 2010 May; 165(2):305-10. PubMed ID: 20153374
[TBL] [Abstract][Full Text] [Related]
6. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
[TBL] [Abstract][Full Text] [Related]
7. Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans.
Nachbagauer R; Wohlbold TJ; Hirsh A; Hai R; Sjursen H; Palese P; Cox RJ; Krammer F
J Virol; 2014 Nov; 88(22):13260-8. PubMed ID: 25210189
[TBL] [Abstract][Full Text] [Related]
8. Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses.
Yoshida R; Igarashi M; Ozaki H; Kishida N; Tomabechi D; Kida H; Ito K; Takada A
PLoS Pathog; 2009 Mar; 5(3):e1000350. PubMed ID: 19300497
[TBL] [Abstract][Full Text] [Related]
9. Exploiting Pan Influenza A and Pan Influenza B Pseudotype Libraries for Efficient Vaccine Antigen Selection.
Del Rosario JMM; da Costa KAS; Asbach B; Ferrara F; Ferrari M; Wells DA; Mann GS; Ameh VO; Sabeta CT; Banyard AC; Kinsley R; Scott SD; Wagner R; Heeney JL; Carnell GW; Temperton NJ
Vaccines (Basel); 2021 Jul; 9(7):. PubMed ID: 34358157
[TBL] [Abstract][Full Text] [Related]
10. Elicitation of Protective Antibodies against 20 Years of Future H3N2 Cocirculating Influenza Virus Variants in Ferrets Preimmune to Historical H3N2 Influenza Viruses.
Allen JD; Jang H; DiNapoli J; Kleanthous H; Ross TM
J Virol; 2019 Feb; 93(3):. PubMed ID: 30429350
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with a Recombinant H7 Hemagglutinin-Based Influenza Virus Vaccine Induces Broadly Reactive Antibodies in Humans.
Stadlbauer D; Rajabhathor A; Amanat F; Kaplan D; Masud A; Treanor JJ; Izikson R; Cox MM; Nachbagauer R; Krammer F
mSphere; 2017; 2(6):. PubMed ID: 29242836
[TBL] [Abstract][Full Text] [Related]
12. Measurement of neutralizing antibody responses against H5N1 clades in immunized mice and ferrets using pseudotypes expressing influenza hemagglutinin and neuraminidase.
Tsai C; Caillet C; Hu H; Zhou F; Ding H; Zhang G; Zhou B; Wang S; Lu S; Buchy P; Deubel V; Vogel FR; Zhou P
Vaccine; 2009 Nov; 27(48):6777-90. PubMed ID: 19732860
[TBL] [Abstract][Full Text] [Related]
13. Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains.
Ryder AB; Nachbagauer R; Buonocore L; Palese P; Krammer F; Rose JK
J Virol; 2015 Dec; 90(5):2544-50. PubMed ID: 26676789
[TBL] [Abstract][Full Text] [Related]
14. Measuring the neutralization potency of influenza A virus hemagglutinin stalk/stem-binding antibodies in polyclonal preparations by microneutralization assay.
He W; Mullarkey CE; Miller MS
Methods; 2015 Nov; 90():95-100. PubMed ID: 25957674
[TBL] [Abstract][Full Text] [Related]
15. Heterosubtypic antibody response elicited with seasonal influenza vaccine correlates partial protection against highly pathogenic H5N1 virus.
Ding H; Tsai C; Zhou F; Buchy P; Deubel V; Zhou P
PLoS One; 2011 Mar; 6(3):e17821. PubMed ID: 21464977
[TBL] [Abstract][Full Text] [Related]
16. A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses.
Jiang W; Wang S; Chen H; Ren H; Huang X; Wang G; Chen Z; Chen L; Chen Z; Zhou P
J Virol; 2017 May; 91(9):. PubMed ID: 28179535
[TBL] [Abstract][Full Text] [Related]
17. Intranasal adenovirus-vectored vaccine for induction of long-lasting humoral immunity-mediated broad protection against influenza in mice.
Kim EH; Park HJ; Han GY; Song MK; Pereboev A; Hong JS; Chang J; Byun YH; Seong BL; Nguyen HH
J Virol; 2014 Sep; 88(17):9693-703. PubMed ID: 24920793
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM
J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689
[TBL] [Abstract][Full Text] [Related]
19. Establishment of retroviral pseudotypes with influenza hemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies.
Wang W; Butler EN; Veguilla V; Vassell R; Thomas JT; Moos M; Ye Z; Hancock K; Weiss CD
J Virol Methods; 2008 Nov; 153(2):111-9. PubMed ID: 18722473
[TBL] [Abstract][Full Text] [Related]
20. Development and Characterization of a Highly Sensitive NanoLuciferase-Based Immunoprecipitation System for the Detection of Anti-Influenza Virus HA Antibodies.
Honda T; Gomi S; Yamane D; Yasui F; Yamamoto T; Munakata T; Itoh Y; Ogasawara K; Sanada T; Yamaji K; Yasutomi Y; Tsukiyama-Kohara K; Kohara M
mSphere; 2021 May; 6(3):. PubMed ID: 33980684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
